Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
about
In Vivo Delivery Systems for Therapeutic Genome EditingIntegrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene EditingGenome editing and the next generation of antiviral therapy.Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.Plant viral and bacteriophage delivery of nucleic acid therapeutics.CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
P2860
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@ast
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@en
type
label
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@ast
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@en
prefLabel
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@ast
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@en
P2093
P2860
P1433
P1476
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic
@en
P2093
Adam L Mefferd
Anand V R Kornepati
Bryan R Cullen
Edward M Kennedy
Hal P Bogerd
Joy B Marshall
P2860
P356
10.1016/J.YMETH.2015.08.012
P50
P577
2015-08-17T00:00:00Z